medicina61巻9号

2024年08月発行

特集 リウマチ膠原病疾患Up To Date！—押さえておきたい最新の診断と治療 膠原病関連症状に対する治療

妊婦・家族計画中におけるリウマチ・膠原病の対応について

著者： 中井健宏¹

所属機関： ¹聖路加国際病院Immuno-Rheumatology Center

ページ範囲：P.1546 - P.1553

Point
◎膠原病合併妊娠ではpreconception careを行い，妊娠に適した内服薬で疾患活動性を安定化し，病状的に必要な最低限のステロイド内服量に減量したうえで妊活を開始することが望ましい．
◎全身性エリテマトーデス（SLE）合併妊娠ではpreeclampsiaのリスクが高く，適切な予防を考慮する．
◎抗SSA抗体陽性妊娠では，新生児ループスに注意が必要である．

参考文献

1）Mai CT, et al：National population-based estimates for major birth defects, 2010-2014. Birth Defects Res 111：1420-1435, 2019 PMID 31580536

2）Peterson EA, et al：Rheumatologic medication use during pregnancy. Obstet Gynecol 135：1161-1176, 2020 PMID 32282595

3）Vargesson N：Thalidomide-induced teratogenesis；History and mechanisms. Birth Defects Res C Embryo Today 105：140-156, 2015 PMID 26043938

4）Henson LJ, et al：Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide. Reprod Toxicol 95：45-50, 2020 PMID 32407881

5）Suzuki S, Eto M：Current status of social problems during pregnancy at a perinatal center in Japan. JMA J 3：307-312, 2020 PMID 33225102

6）Wei Q, et al：Pregnancy complicating systemic lupus erythematosus；A series of 86 cases. Arch Gynecol Obstet 284：1067-1071, 2011 PMID 21136266

7）Habbema JDF, et al：Realizing a desired family size；When should couples start? Hum Reprod 30：2215-2221, 2015 PMID 26185187

8）Tsuda S, et al：Pre-conception status, obstetric outcome and use of medications during pregnancy of systemic lupus erythematosus（SLE）, rheumatoid arthritis（RA）and inflammatory bowel disease（IBD）in Japan；Multi-center retrospective descriptive study. Mod Rheumatol 30：852-861, 2019 PMID 31483178

9）de Man YA, et al：Disease activity of rheumatoid arthritis during pregnancy；Results from a nationwide prospective study. Arthritis Rheum 59：1241-1248, 2008 PMID 18759316

10）Hellgren K, et al：Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis；A matched cohort study from Sweden and Denmark. Rheumatology（Oxford）61：3711-3722, 2022 PMID 34864891

11）Mehta B, et al：Trends in maternal and fetal outcomes among pregnant women with systemic lupus erythematosus in the United States. Ann Intern Med 171：164-171, 2019 PMID 31284305

12）Nakai T, et al：Risk of adverse pregnancy outcomes in Japanese systemic lupus erythematosus patients with prior severe organ manifestations；A single-center retrospective analysis. Lupus 30：1415-1426, 2021 PMID 34013819

13）Buyon JP, et al：Predictors of pregnancy outcomes in patients with lupus；A cohort study. Ann Intern Med 163：153-163, 2015 PMID 26098843

14）Palma dos Reis CR, et al：Prediction of adverse pregnancy outcomes in women with systemic lupus erythematosus. Clin Rev Allergy Immunol 59：287-294, 2020 PMID 31444781

15）Kim JW, et al：Lupus low disease activity state achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus. J Rheumatol 48：707-716, 2021 PMID 33060317

16）Tani C, et al：Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study. Rheumatology（Oxford）60：5610-5619, 2021 PMID 33590843

17）Huang H, et al：Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus；A retrospective observational study. Arthritis Res Ther 23：275, 2021 PMID 34715915

18）Nakai T, et al：Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus. Arthritis Res Ther 26：63, 2024 PMID 38459603

19）Yamamoto Y, Aoki S：Systemic lupus erythematosus；Strategies to improve pregnancy outcomes. Int J Womens Health 8：265-272, 2016 PMID 27468250

20）Zeisler H, et al：Predictive value of the sFlt-1：PlGF ratio in women with suspected preeclampsia. N Engl J Med 374：13-22, 2016 PMID 26735990

21）Armaly Z, et al：Preeclampsia；Novel mechanisms and potential therapeutic approaches. Front Physiol 9：973, 2018 PMID 30090069

22）Rolnik DL, et al：Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 377：613-622, 2017 PMID 28657417

23）Sammaritano LR, et al：2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72：529-556, 2020 PMID 32090480

24）Roberge S, et al：Aspirin for the prevention of preterm and term preeclampsia；Systematic review and metaanalysis. Am J Obstet Gynecol 218：287-293.e1, 2018 PMID 29138036

25）Giles I, et al：Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nat Rev Rheumatol 15：391-402, 2019 PMID 31186540

26）Mithal LB, et al：Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. Am J Obstet Gynecol 225：192-194, 2021 PMID 33812808

27）Izmirly PM, et al：Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 124：1927-1935, 2011 PMID 21969015

28）Izmirly PM, et al：Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system. Ann Rheum Dis 75：1161-1165, 2016 PMID 26835701

29）Pisoni CN, et al：Failure of intravenous immunoglobulin to prevent congenital heart block；Findings of a multicenter, prospective, observational study. Arthritis Rheum 62：1147-1152, 2010 PMID 20131278

30）Izmirly P, et al：Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA/Ro-positive mothers. J Am Coll Cardiol 76：292-302, 2020 PMID 32674792

31）Cuneo BF, et al：Home monitoring for fetal heart rhythm during anti-Ro pregnancies. J Am Coll Cardiol 72：1940-1951, 2018 PMID 30309472

32）Buyon JP, et al：Prospective evaluation of high titer autoantibodies and fetal home monitoring in the detection of atrioventricular block among anti-SSA/Ro pregnancies. Arthritis Rheumatol 76：411-420, 2023 PMID 37947364

33）Russell MD, et al：British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding：immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology（Oxford）62：e48-e88, 2023 PMID 36318966

34）Skorpen CG, et al：The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 75：795-810, 2016 PMID 26888948

35）Ramoni VL, et al：Changes to expert opinion in the use of antirheumatic drugs before and during pregnancy five years after EULAR；Points to consider. Rheumatology（Oxford）61：e331-e333, 2022 PMID 35587743

36）Jesam C, et al：Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor；Potential for emergency contraception. Hum Reprod 25：368-373, 2010 PMID 19933235

37）Dathe K, et al：Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs：a literature review. Eur J Clin Pharmacol 75：1347-1353, 2019 PMID 31273431

38）Brouwer J, et al：Fertility in women with rheumatoid arthritis：Influence of disease activity and medication. Ann Rheum Dis 74：1836-1841, 2015 PMID 24833784

39）Shimada H, et al：Preterm birth is strongly affected by the glucocorticoid dose during pregnancy in women complicated by systemic lupus erythematosus. Arthritis Res Ther 24：10, 2022 PMID 34980235

40）Yao TC, et al：Association between antenatal corticosteroids and risk of serious infection in children；Nationwide cohort study. 382：e075835, 2023 PMID 37532264

41）Saavedra MÁ, et al：Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. Clin Rheumatol 34：1211-1216, 2015 PMID 26050103

42）Kitada A, et al：Safety of tacrolimus use during pregnancy and related pregnancy outcomes in patients with systemic lupus erythematosus；A retrospective single-center analysis in Japan. Lupus 32：352-362, 2023 PMID 36633400

43）Suzuki K, et al：Tacrolimus use and renal function in pregnancy with lupus nephritis；Analysis of post-marketing surveillance data in Japan. Mod Rheumatol 33：944-952, 2023 PMID 35982545

44）Hiramatsu Y, et al：Changes in the blood level, efficacy, and safety of tacrolimus in pregnancy and the lactation period in patients with systemic lupus erythematosus. Lupus 27：2245-2252, 2018 PMID 30394835

45）Nakai T, et al：A retrospective analysis of the safety of tacrolimus use and its optimal cut-off concentration during pregnancy in women with systemic lupus erythematosus；Study from two Japanese tertiary referral centers. Arthritis Res Ther 26：15, 2024 PMID 38178242

46）Jain A, et al：Pregnancy after liver transplantation under tacrolimus. Transplantation 64：559-565, 1997 PMID 9293865

47）Ghalandari N, et al：Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis 81：402-405, 2022 PMID 34493490

48）Juliao P, et al：Belimumab use during pregnancy；Interim results of the belimumab pregnancy registry. Birth Defects Res 115：188-204, 2023 PMID 36177676

49）Petri M, et al：Belimumab use during pregnancy；A summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. Ann Rheum Dis 82：217-225, 2023 PMID 36198440

50）Kao JH, et al：Pregnancy outcomes in patients treated with belimumab；Report from real-world experience. Semin Arthritis Rheum 51：963-968, 2021 PMID 34403811

51）Nakai T, et al：A case report of two systemic lupus erythematosus pregnancies with early placental exposure to belimumab；Case report with review. Mod Rheumatol Case Rep 7：82-86, 2023 PMID 36029470

52）Danve A, et al：Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-A case report. Semin Arthritis Rheum 44：195-197, 2014 PMID 25005336